Cognitact provide a blood-based protein biomarkers analysis service for AD early detection— PlasmarkAD®. PlasmarkAD® achieves early detection of AD at 5-10 years with the accuracy of over 96% before symptoms appear.
Mid-to-long-term follow-up testing plan to continuously monitor your cognitive level and AD risk.
View Details
Package for family members, friends, or companies. (In the form of vouchers)
View Details
Details:
1. Log in https://www.cognitact.com, purchase the testing service, and complete the payment.
2. Go to "My Order", select your desired time and testing centre, and make an appointment for testing.
3. We will take a small blood sample for you at the time and place of your appointment. Based on our latest research results, the amount of blood required for the test is only 3mL.
4. At the same time as the blood sample is taken, our professional consultant will help you to carry out an eCogmark®* cognitive assessment.
5. Your blood sample will be immediately sent to our laboratory for blood protein analysis using Contech's proprietary PlasmarkAD® technology, and your own brain health report will be compiled for you
6. After the test report is completed, we will notify you by SMS and email. You can download and view your report in real time, or go to our test center to collect your report in person. Your report will be kept strictly confidential and no third party will have access to or view it without your permission.
* eCogmark® is an international cognitive assessment test standard
used to assist in assessing an individual's cognitive status.
We strongly recommend initiating continuous monitoring of brain health staring at the age of 55, and timely measures to maintain and enhance cognitive health and vitality. We believe that PlasmarkAD® technology will provide you with a more accurate, convenient and reliable analysis of the potential risk of Alzheimer's disease, helping you maintain health and vitality in your later years.
By analyzing a large number of blood samples from specific populations, we have established a deep learning based scoring system that can analyse and evaluate human blood information to predict the risk of developing Alzheimer's disease. This method can effectively improve the prediction accuracy and more effectively predict the early symptoms of the disease, providing effective support for timely treatment. In addition, this system can also be used for early prediction and treatment of other diseases.
Based on our continuous research results, we have discovered a special group of blood Using biomarkers to diagnose Alzheimer's disease (AD). These biomarkers exhibit strong signal characteristics in individuals with AD. By using deep learning techniques, we have successfully established a system for this marker, with an accuracy of 96%. This study helps improve the diagnosis and treatment of Alzheimer's disease, while also providing new avenues for related research and prediction
Our nearly three decades of research in the field of Alzheimer's disease can not only help you to grasp your current situation more accurately, but also provide you with more targeted suggestions for improvement to help you better control and avoid the risks of disease.
2023 by Cognitact Ltd.All right reserved.
